Please assess the completion status of the following clinical trial:

Trial Title: Metoclopramide as Treatment of Clozapine-induced Hypersalivation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-60 years, male or female~* DSM-IV criteria for schizophrenia~* Clozapine treatment~* At least score \>2 on the Nocturnal Hypersalivation Rating Scale (NHRS)~Exclusion Criteria:~* Evidence of organic brain damage, mental retardation, alcohol or drug abuse~* Patients suffering from pheochromocytoma~* Patients suffering from Parkinson's disease

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 57 Years
- Healthy Volunteers: f

Study Arms:
- metoclopramide (Type: PLACEBO_COMPARATOR): 61 participating subjects were randomized into 2 groups: 30 received metoclopramide up to 30 mg/day and 31 received placebo, each for 4 weeks in a double-blind mode
- metocliopramide (Type: EXPERIMENTAL): 61 participating subjects were randomized into 2 groups: 30 received metoclopramide up to 30 mg/day and 31 received placebo, each for 4 weeks in a double-blind mode

Based on this trial design, predict the completion outcome and termination type (if applicable).